2019 – gabarx.com

GABA Therapeutics Receives Approval to Begin Phase I Clinical Trials
Gallery
GABA Therapeutics Receives Approval to Begin Phase I Clinical Trials

Press Coverage, Uncategorized

GABA Therapeutics Receives Approval to Begin Phase I Clinical Trials

We are pleased to provide some positive updates. Inaugural Board Meeting The company held its first Board of Directors meeting in San Francisco in early November. Attendees included (left to right): Srini Rao M.D., Ph.D, Chief Medical Officer, GABA Therapeutics Ian Massey, D.Phil, CEO and Director, GABA Therapeutics Richard [...]

Richard Farrell2019-12-17T22:41:19+00:00Press Coverage, Uncategorized|

GABA Therapeutics and ATAI Life Sciences Partner to Develop a Novel GABA Modulator for the Treatment of Mood Disorders

Press Coverage, Press Release

GABA Therapeutics and ATAI Life Sciences Partner to Develop a Novel GABA Modulator for the Treatment of Mood Disorders

NEWPORT BEACH, Calif. and BERLIN, Sept. 20, 2019 /PRNewswire/ -- Today, GABA Therapeutics, a biotech company focused on the treatment of mood disorders, and ATAI Life Sciences, a global biotech company builder working on paradigm shifting interventions for unmet needs in the mental health space, announced a partnership to develop a novel compound that promises [...]

Richard Farrell2019-11-08T19:50:04+00:00Press Coverage, Press Release|